USE OF GENOMICS AND PROTEOMICS IN PHARMACEUTICAL DRUG DISCOVERY AND DEVELOPMENT: A REVIEW
Sharma Neha, S. L. Harikumar Rayat · 2013
One of the most pressing issues facing the pharmaceutical industry is the tremendous dropout rate of lead drug candidates. Genomics and proteomics are today well established in drug discovery and development, in combination with combinatorial chemistry and high-throughput screening, are helping to bring forward a matchless number of potential lead compounds. Over the last two decades, several new genomic technologies have been developed in hopes of addressing the issues of target identification and lead candidate optimization. Proteomics is a technology platform that is gaining widespread use in drug discovery and drug development programs. Defined as the protein complement of the genome, the proteome is a varied and dynamic repertoire of molecules that in many ways dictates the functional form that is taken by the genome. We focus in this article on recent progress and innovations utilizing “omics” technologies to identify and validate drug targets, discover disease biomarkers, and design more effective drugs.